Skip to main content

Plaintiff Claims That Recalled Valsartan Led To Liver Cancer

Plaintiff Claims That Recalled Valsartan Led To Liver Cancer

Plaintiff Claims That Recalled Valsartan Led To Liver Cancer

Introduction

A plaintiff filed a lawsuit against generic drug makers of Valsartan in the U.S. District Court for the District of New Jersey, alleging that he was diagnosed with liver cancer due to its side effects.

According to the complaint filed, generic drug makers like Zhejiang Huahai Pharmaceutical, Co., Princeton Pharmaceutical, Solco Healthcare, and Walgreens Boots Alliance were responsible for distributing contaminated blood pressure pills. The plaintiff indicated that he took generic valsartan-containing drugs (VCDs) in August 2016, for the treatment of high blood pressure and continued to take pills until July 2018, when it was discovered that the pills were contaminated with cancer-causing chemicals that were a byproduct of the manufacturing process.

The case joins a growing number of valsartan lawsuits filed in recent months by individuals indicating that they were left with a number of other types of cancer, including liver cancer, kidney cancer, gastric cancer, pancreatic cancer, and other injuries following exposure to NDMA or NDEA.

Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!